Association between the rs3802201 polymorphism of the lncRNA MIR2052HG gene and the risk of recurrent miscarriage in a Southern Chinese population.
MIR2052HG
recurrent miscarriage
single nucleotide polymorphism
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
01
11
2021
received:
25
08
2021
accepted:
23
11
2021
pubmed:
16
12
2021
medline:
22
3
2022
entrez:
15
12
2021
Statut:
ppublish
Résumé
Plenty of studies have indicated that some genetic polymorphisms of the breast cancer which associated with its susceptibility may also be related to the susceptibility of abortion. MIR2052HG plays an important role in the onset and progression of breast cancer by maintaining the level of ERα, but to the best of our knowledge, the correlation between risk of recurrent abortion and MIR2052HG rs3802201 C>G polymorphism is still unclear. Therefore, we conducted this case-control study to investigate whether MIR2052HG rs3802201 C>G polymorphism is associated with susceptibility of recurrent miscarriage (RM). We recruited 392 healthy controls and 248 patients with RM to process this research, the participants were all from southern China, and genotyping was performed by TaqMan method. Our results showed that there was no evidence indicates the MIR2052HG rs3802201 C>G is related to RM (CG and CC: adjusted OR = 0.970, 95% CI = 0.694-1.355, p = 0.8577; GG and CC: adjusted OR = 0.743, 95% CI = 0.416-1.330, p = 0.3174; dominant model: adjusted OR = 0.925, 95% CI = 0.672-1.272, p = 0.6298; recessive model: adjusted OR = 0.751, 95% CI = 0.430-1.321, p = 0.3233). We verified that the MIR2052HG rs3802201 C>G allele might be uncorrelated to the RM risk, but these findings require further validation in multicenter studies with larger sample size and different ethnicities.
Sections du résumé
BACKGROUND
BACKGROUND
Plenty of studies have indicated that some genetic polymorphisms of the breast cancer which associated with its susceptibility may also be related to the susceptibility of abortion. MIR2052HG plays an important role in the onset and progression of breast cancer by maintaining the level of ERα, but to the best of our knowledge, the correlation between risk of recurrent abortion and MIR2052HG rs3802201 C>G polymorphism is still unclear. Therefore, we conducted this case-control study to investigate whether MIR2052HG rs3802201 C>G polymorphism is associated with susceptibility of recurrent miscarriage (RM).
METHODS
METHODS
We recruited 392 healthy controls and 248 patients with RM to process this research, the participants were all from southern China, and genotyping was performed by TaqMan method.
RESULTS
RESULTS
Our results showed that there was no evidence indicates the MIR2052HG rs3802201 C>G is related to RM (CG and CC: adjusted OR = 0.970, 95% CI = 0.694-1.355, p = 0.8577; GG and CC: adjusted OR = 0.743, 95% CI = 0.416-1.330, p = 0.3174; dominant model: adjusted OR = 0.925, 95% CI = 0.672-1.272, p = 0.6298; recessive model: adjusted OR = 0.751, 95% CI = 0.430-1.321, p = 0.3233).
CONCLUSION
CONCLUSIONS
We verified that the MIR2052HG rs3802201 C>G allele might be uncorrelated to the RM risk, but these findings require further validation in multicenter studies with larger sample size and different ethnicities.
Identifiants
pubmed: 34910326
doi: 10.1002/jcla.24167
pmc: PMC8761428
doi:
Substances chimiques
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24167Subventions
Organisme : Guangdong Provincial Science and Technology Plan
ID : 2017A030223003
Organisme : Guangzhou Medical and Health Technology Projects
ID : 20191A011021
Organisme : Guangzhou Medical and Health Technology Projects
ID : 20191A011033
Organisme : Guangdong Natural Science Foundation
ID : 2019A1515012061
Organisme : Guangzhou Institute of Pediatrics/Guangzhou Women and Children's Medical Center Fund
ID : YIP-2019-050
Organisme : Guangzhou Science and Technology Program Key Projects
ID : 201904010486
Organisme : Guangzhou Health Commission
ID : 20211A011034
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Front Physiol. 2019 Apr 09;10:385
pubmed: 31024342
J Natl Cancer Inst. 2004 Mar 17;96(6):434-42
pubmed: 15026468
J Cell Physiol. 2019 Nov;234(11):20577-20583
pubmed: 30982978
Fertil Steril. 2017 Jan;107(1):150-159.e2
pubmed: 27842992
Lancet. 2006 Aug 12;368(9535):601-11
pubmed: 16905025
J Assist Reprod Genet. 2018 Mar;35(3):355-366
pubmed: 29313278
Nat Genet. 2018 Dec;50(12):1705-1715
pubmed: 30349115
Reprod Sci. 2015 Apr;22(4):410-5
pubmed: 24700052
Clin Genet. 2017 Feb;91(2):265-284
pubmed: 27792840
Front Genet. 2019 Oct 04;10:918
pubmed: 31636654
Semin Reprod Med. 2015 May;33(3):161-8
pubmed: 26036897
Med Princ Pract. 2015;24 Suppl 1:38-55
pubmed: 25428171
Fertil Steril. 2010 Mar 1;93(4):1234-43
pubmed: 19338986
Ann Clin Lab Sci. 2017 May;47(3):291-297
pubmed: 28667029
Reprod Biol Endocrinol. 2014 Jul 27;12:70
pubmed: 25064236
PLoS Genet. 2008 May 09;4(5):e1000072
pubmed: 18464913
Nat Med. 2011 Jun;17(6):715-9
pubmed: 21602804
Cancer Res. 2016 Dec 1;76(23):7012-7023
pubmed: 27758888
J Clin Lab Anal. 2022 Jan;36(1):e24167
pubmed: 34910326
J Clin Lab Anal. 2019 Jul;33(6):e22919
pubmed: 31124188
Am J Reprod Immunol. 2014 Dec;72(6):577-85
pubmed: 25203601
Am J Reprod Immunol. 2012 Apr;67(4):341-7
pubmed: 22390536
Per Med. 2018 Jul 1;15(4):279-289
pubmed: 29965793
Am J Reprod Immunol. 2014 Oct;72(4):359-75
pubmed: 24916667
Clin Chim Acta. 2017 Jan;464:17-23
pubmed: 27836685
J Clin Lab Anal. 2019 Nov;33(9):e22992
pubmed: 31454102
Obstet Gynecol Clin North Am. 2015 Mar;42(1):117-34
pubmed: 25681844
Int J Mol Sci. 2021 Apr 15;22(8):
pubmed: 33920789
Am J Epidemiol. 2002 Jul 15;156(2):95-109
pubmed: 12117698
Pharmacogenetics. 2000 Mar;10(2):115-22
pubmed: 10761999
Onco Targets Ther. 2019 Dec 05;12:10671-10679
pubmed: 31824174
Lancet. 1990 Sep 15;336(8716):673-5
pubmed: 1975862
BMC Med Genet. 2012 Dec 13;13:121
pubmed: 23237535
Int J Immunogenet. 2018 Aug;45(4):181-189
pubmed: 29797531